Nourkrin® is committed to ensuring its continued recognition as a benchmark for excellence – not only by consumers, but also by scientists, dermatologists, and health care professionals worldwide.
Nourkrin® is based on more than 100 scientific studies and clinical papers published in leading peer-review journals.
Nourkrin® continues to partner with the world’s leading authorities on hair loss and hair thinning, based on its clinically documented efficacy and safety standards.
Nourkrin® contains naturally based ingredients that have been scientifically documented to be safe and effective.*
Nourkrin® is committed to increasing treatment results for all patients suffering from hair growth disorders or hair loss. Therefore, following the clinical establishment of Proteoglycan Follicular Atrophy as being a major underlying negative contributor, the primary focus of the research presented is focussed on Proteoglycan Follicular Atrophy, Follicular Hypo-Glycania and clinically validated and proven Proteoglycan Replacement Therapy.
Nourkrin® has been tested in placebo, double-blind studies and shown to be side effect free.* This is in contrast to other pharmaceuticals, which may cause; scalp itching, dryness, scaling, flaking, irritation, burning and in extreme instances weight gain, swelling of the face, ankles, hands or stomach, difficulty breathing (especially when lying down), rapid heartbeat, chest pain and light-headedness.**
Conclusion: Controlled evaluation of monotherapy with Nourkrin® with Marilex® evidenced a significant improvement in both hair density and treatment satisfaction compared to both baseline values and the placebo group. It is important to consider that the observed increase in scalp hair count was time-dependent and reached statistical significance after 6 months of treatment. It continued to improve throughout the 12-months follow up period of this trial.
These findings indicate that long-term treatment (6 months or more) with Nourkrin® is preferable for satisfactory results. No significant adverse effects were detected and none of the participants withdrew from the study because of side effects.
Conclusion: Female Pattern Hair Loss (FPHL) and Telogen Effluvium (TE) are the most common types of hair loss in women, yet their underlying causes are not convincingly explained. This milestone paper sheds light on a fundamental pathology that is behind several clinical presentations of hair growth disorders in women. Research shows that the ability of the affected follicular cells to synthesise proteoglycans declines considerably. This leads to a proteoglycan deficient state called Follicular Hypo-Glycania (FHG). This pathological state negatively affects multiple key metabolic pathways such as Wnt/β-catenin; thereby shortening the Anagen phase and inducing hair follicles to enter a dormant Telogen phase. Long-lasting, untreated FHG causes follicular miniaturisation and atrophy, a condition called Proteoglycan Follicular Atrophy (PFA). This recently recognised condition responds to treatment with Nourkrin® with Marilex®. The authors suggest that Nourkrin® therapy delivers bioactive proteoglycans that can force hair follicles to enter Anagen and prolong hair growth by promoting cell proliferation. The clinical efficacy of PRT was proven through several human trials where Nourkrin® not only increased hair density of women with FPHL but also improved their self-esteem, psychosocial wellbeing and overall quality of life.
Conclusion: This trial highlights, a critically important but widely neglected aspect, the effects of hair loss on psychological well-being and quality of life. In women with Ludwig type-I to type-III hair loss, treatment with Nourkrin® for 6 months improved all indices of quality of life. This psychological improvement did occur with an improvement in the cosmetic status of participants. Clinicians should also take this effect of Nourkrin® into account when considering the cost-benefit evaluation of the treatment.
Conclusion: This review provides a focused overview of the function of specific proteoglycans in the hair follicle and their relevance in the pathophysiology of common hair growth disorders. With reference to the close involvement of proteoglycans in the biology of the hair follicle and considering their improving effects on hair pathologies, the authors proposed using specific bioavailable mixtures of proteoglycans (Marilex® in Nourkrin®) for the prevention and treatment of common types of hair loss.
Conclusion: This review sheds light on the underlying mechanisms of Postpartum Telogen Effluvium and explains why the depletion of follicular proteoglycans is a potential underlying aetiology. The author argues that, based on the available evidence, dramatic fluctuations in the level of sex hormones and cortisol, during and shortly after pregnancy, can influence the homeostasis of follicular proteoglycans, which in turn leads to significant Anagen shortening and cycling disruption. Hence, Proteoglycan Replacement Therapy with Nourkrin® is proposed to treat Postpartum Telogen Effluvium.
Conclusion: This review explores different factors involved in hair cycle disruption following acute or chronic stress, i.e., in Telogen Effluvium, highlighting a less-studied relationship between the stress hormone, cortisol, and follicular proteoglycans. There is evidence to show that the enhanced rate of degradation of proteoglycans (Proteoglycan Follicular Atrophy), secondary to high concentrations of circulating cortisol, explains the association between stress and hair loss in Acute and Chronic Telogen Effluvium. A Proteoglycan Replacement Therapy (Nourkrin® with Marilex® from Pharma Medico), featuring versican and decorin specifically, can play a pivotal role in the induction and prolongation of the Anagen phase of the Hair Growth Cycle during stress-induced Acute and Chronic Telogen Effluvium.
Conclusion: This paper describes the common aetiological aspects and shared risk factors of hair loss and chronic lifestyle disorders e.g., insulin resistance syndromes. It appears that Androgenetic Alopecia is an independent risk factor for metabolic syndrome and coronary artery disease, given the fact that insulin resistance and inflammation can negatively affect the normal homeostasis of the hair follicle. Being aware of such an association justifies the importance of implementing a multidisciplinary approach towards diagnosis and treatment of hair loss. With its unique anti-inflammatory and hair regrowth properties, PRT with Nourkrin® provides an additional dimension to the management of hair loss accompanied by insulin resistance syndromes. Effective treatment of hair loss by PRT also contributes to alleviating psychological stress, which can aggravate both of these associated conditions.
Conclusion: Treating Female Diffuse Hair Loss Using Nourkrin® Woman (with Marilex®) – An Open-Label, Subjective, Outcome Study on Hair Growth and Appearance, Self-Confidence and Treatment Satisfaction
Conclusion: The majority of participants in this recently published, qualitative study expressed their satisfaction with Nourkrin® therapy. In particular, treated individuals experienced a positive change in the quality and appearance of their hair as early as 3 months into the study. Patients’ satisfaction in both cosmetic and psychological aspects continued to rise with longer treatment durations. It can be concluded from this study that, in women with FPHL and TE, high satisfaction rates are achieved by a 6-month or longer treatment period with Nourkrin® Woman.
Conclusion: In this long-term, subjective, clinical study, the therapeutic efficacy of PRT with Nourkrin® was evaluated from a patient-centred point of view in a Brazilian population. A notable strength of this study was that, along with hair growth and appearance, researchers also assessed psychological outcomes such as patients’ confidence and treatment satisfaction. Research findings clearly demonstrated that the condition of hair had improved in the majority of participants after a course of monotherapy with Nourkrin®. Observations also suggest that the positive effects of PRT can emerged just after 3 months, which shows a shorter delay compared to conventional hair loss treatments. A high level of efficacy and short time of onset are presumably the main factors that led to a high treatment satisfaction rate of 97% with Nourkrin® treatment. More importantly, the enhanced hair confidence induced by PRT can improve patients’ self-image and prevent psychosocial consequences of hair loss. This clinical study confirms that monotherapy with Nourkrin® is an effective approach towards hair loss treatment in women.
© Nourkrin®. ALL RIGHTS RESERVED. Nourkrin® is a brand from Pharma Medico.
Read the nourkrin.co.uk Terms & Conditions and Privacy Policy.
Do you need help, information, or just want to get in touch with us?
Call us on:
01 626 2315 or
0044 1782 793050
Visit these pages for further reading: